Expression of microRNA-208 is Associated With Adverse Clinical Outcomes in Human Dilated Cardiomyopathy

Satoh, Mamoru; Minami, Yoshitaka; Takahashi, Yūji; Tabuchi, Tsuyoshi; Nakamura, Motoyuki

doi:10.1016/j.cardfail.2010.01.002

Cited by 109 publications

(88 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Importantly, miR-133 and miR-208, which are strongly associated with cardiac hypertrophy and fibrosis, were unchanged in both HF entities. This observation puts a question mark behind the robustness of clinical miRNA quantification, especially, when looking at results of a different working group: the authors reported elevated miR-208 levels in cardiac tissue of DCM patients and identified miR-208 to be a strong predictor of clinical outcome [71]. Nevertheless, the reported data suggest a specific dysregulation of distinct miRNAs in disease entities of CVD.…”

Section: Mirnas In Heart Failurementioning

confidence: 99%

microRNAs in cardiovascular disease – clinical application

Schulte

Karakas

Zeller

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

104

View full text Add to dashboard Cite

microRNAs (miRNAs) are well-known, powerful regulators of gene expression, and their potential to serve as circulating biomarkers is widely accepted. In cardiovascular disease (CVD), numerous studies have suggested miRNAs as strong circulating biomarkers with high diagnostic as well as prognostic power. In coronary artery disease (CAD) and heart failure (HF), miRNAs have been suggested as reliable biomarkers matching up to established protein-based such as cardiac troponins (cT) or natriuretic peptides. Also, in other CVD entities, miRNAs were identified as surprisingly specific biomarkers -with great potential for clinical applicability, especially in those entities that lack specific protein-based biomarkers such as atrial fibrillation (AF) and acute pulmonary embolism (APE). In this regard, miRNA signatures, comprising a set of miRNAs, yield high sensitivity and specificity. Attempts to utilize miRNAs as therapeutic agents have led to promising results. In this article, we review the clinical applicability of circulating miRNAs in CVD. We are giving an overview of miRNAs as biomarkers in numerous CVD entities to depict the variety of their potential clinical deployment. We illustrate the function of miRNAs by means of single miRNA examples in CVD.

show abstract

Section: Mirnas In Heart Failurementioning

confidence: 99%

microRNAs in cardiovascular disease – clinical application

Schulte

Karakas

Zeller

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

104

View full text Add to dashboard Cite

show abstract

“…Wang et al demonstrated that circulating miRNA 208a can be used to detect acute myocardial infarction with high sensitivity and specificity [22]. In addition, overexpression of miRNA 208a predicts poor clinical outcome in patients with dilated cardiomyopathy [23]. Therefore, our results suggest a biomarker role for circulating miRNA 208a to support the diagnosis of the severity of atrial fibrillation status, keeping in mind, that a significant proportion of patients gets misclassified by clinical categorization [24].…”

Section: Discussionmentioning

confidence: 52%

MicroRNA 208 in Atrial Fibrillation

Hanke¹

2014

J Clin Exp Cardiolog

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are critical regulators of most major cellular processes and seem to play a vital role in the pathogenesis of numerous diseases including atrial fibrillation, the most commonly encountered cardiac rhythm disorder. Among the several miRNAs that appear to be involved in pathogenesis of atrial fibrillation, miRNA 208a is linked to fibrosis and proper cardiac conduction.We quantified the expression levels of miRNA 208a in left atrial appendage tissue of patients with paroxysmal (n=2), persistent (n=10), and long-standing persistent (n=7) arrhythmia using quantitative PCR. In paroxysmal atrial fibrillation, miRNA 208a was expressed moderately, whereas the expression was enhanced in persistent atrial fibrillation and significantly reduced in long-standing persistent atrial fibrillation. The difference between persistent and long-standing persistent atrial fibrillation was significant at p=0.02.The findings from our study suggest a decline in miRNA 208a expression with ongoing arrhythmia, possibly preceded by a rise in expression from paroxysmal to persistent atrial fibrillation or even long-standing persistent. The significant changes in miRNA 208a expression over the course of the disease may be used as an additional diagnostic tool to monitor the progression of atrial fibrillation.

show abstract

“…One study documented increased expression of miR-208, miR208b and miR-499 in myocardial samples obtained by biopsy in human patients with dilated cardiomyopathy compared to the samples from the control group. Levels of α-heavy chain myosin messenger RNA were lower in DCM patients, whereas the β-heavy chains levels were higher and were associated with greater volumes of collagen in the myocardium (SATOH et al, 2010). In other research, ZHOU et al (2010) observed a significant increase in the risk of dilated cardiomyopathy in people with overexpression of some pre-microRNAs, as a consequence of common polymorphism of a single nucleotide, including miR196a2 and HSA-miR-499, which influenced several genes with different functions.…”

Section: Cardiomyopathies In Dogsmentioning

confidence: 90%

“…This may be explained in part by the small number of animals in the study or by the type of sample analyzed. In contrast, several studies in people have used cardiac tissue samples instead of blood samples, since microRNAs are expressed differently in various tissues and cells (SATOH et al, 2010;POWERS et al, 2015).…”

Section: Cardiomyopathies In Dogsmentioning

confidence: 99%

“…MicroRNA 208 is encoded by the heavy chain myosin gene and is closely involved in myosin regulation and myocardial fibrosis, as well as being involved in the progression of DCM in people (IKEDA & PU, 2010;SATOH et al, 2010). One study documented increased expression of miR-208, miR208b and miR-499 in myocardial samples obtained by biopsy in human patients with dilated cardiomyopathy compared to the samples from the control group.…”

Section: Cardiomyopathies In Dogsmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNAs in veterinary cardiology

2017

View full text Add to dashboard Cite

The use of biomarkers is an important recent development in veterinary medicine. Biomarkers allow non-invasive quantification of substances with diagnostic and prognostic potential in several diseases. The microRNAs are small, non-coding RNAs that regulate gene expression and are expressed in different forms in many diseases. Reduced or over-expression of microRNAs showed to be part of the pathogenesis of some heart diseases in humans and animals. Diagnostic and therapeutic value of measuring microRNAs in veterinary cardiology is increased because abnormal expression can be managed by the use of antagonists (in the case of overexpression) and mimicking (in the case of underexpression). Thus, this literature review aimed to compile scientific evidence of dysregulation of microRNAs expression in different cardiac diseases being one of the promises in the therapeutic field and diagnosis of veterinary cardiology. MicroRNAs not only have potential as a biomarker but may also help in elucidation of aspects of the pathogenesis of a variety of diseases.

show abstract

Expression of microRNA-208 is Associated With Adverse Clinical Outcomes in Human Dilated Cardiomyopathy

Cited by 109 publications

References 27 publications

microRNAs in cardiovascular disease – clinical application

microRNAs in cardiovascular disease – clinical application

MicroRNA 208 in Atrial Fibrillation

MicroRNAs in veterinary cardiology

Contact Info

Product

Resources

About